April 2nd 2025
A mail campaign targeting adults with chronic conditions as well as their GPs increased the number receiving at least 1 shot by 9.5 percentage points.
March 26th 2025
The FDA granted fast track designation to Sanofi’s chlamydia vaccine candidate today, aiming to prevent infections and address an unmet public health need.
March 19th 2025
CROI 2025: Increased HPV vaccine coverage could reduce HIV cases by thousands, according to a new study.
February 27th 2025
Your daily dose of the clinical news you may have missed.
February 24th 2025
The Metrix COVID/Flu molecular test detects and differentiates SARS-CoV-2, influenza A, and influenza B in approximately 20 minutes.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
RSV Mortality Higher than for Influenza B 90 Days After Hospital Discharge: New Data
Older adults hospitalized with RSV were older, more frail, and more likely to have respiratory comorbidities than those with influenza A or B, the study found.
More than One-Third of US Adults Say They "Don't Need" Respiratory Virus Vaccines this Fall
Adults saying they don't need immunization this fall have received the vaccines in the past, survey authors report, suggesting a lingering misinformation effect.
RSV Vaccine Effective Against Hospitalization in Older Adults: Daily Dose
ACIP Highlights Evidence Supporting Recommendation for PCV21 Vaccine for Adults
New report includes data on the safety and immunogenicity of the recently-approved PCV21 vaccine.
Co-administration of Arexvy and Shingrix Yields Positive Topline Phase 3 Data, GSK Reports
Immune responses for both vaccines were noninferior when given at the same visit compared with separate administration among adults aged 50 years and older.
GSK mRNA Flu Vaccine Candidate Delivers Favorable Topline Phase 2 Findings, Ready for Phase 3
The GSK reformulation induced acceptable immune responses for both influenza A and B strains, overcoming a setback earlier in the ability to successfully neutralize the latter.
RSV Vaccine Proves 75% Effective Against Hospitalization in Older Adults, According to New CDC Data
The new data amend that from prelicensure trials, which did not include fair representation of older adults and others more vulnerable to severe RSV disease.
CDC COVID-19 Vaccine Bridge Access Program Ends 4 Months Earlier than Planned
The Bridge Access Program allowed Americans who are uninsured or underinsured to receive COVID-19 vaccination at not cost and was ended abruptly last month.
Moderna launches COVID booster campaign
The “Do It For You & Them” campaign focuses on the impact that virus has on day-to-day lives.
Pfizer Has Launched PfizerForAll, an Online Multipronged Direct-to-Consumer Service
PfizerForAll offers telehealth and prescription services, vaccination scheduling and savings programs, and is partnering with recognized companies such as InstaCart.
Respiratory Virus Vaccines: A Q&A With AAFP President Steven Furr, MD
Topics include declining vaccine coverage among kindergarten-aged children and key changes in recommendations for adult vaccination.
Mpox Outbreak: 5 Things to Know if Patients Ask
Now that the WHO has declared a second mpox global emergency, you may want to brush up on knowledge of the disease and the 2024 outbreak.
8 Questions on Updates to the 2024 ACIP Adult Immunization Schedule
Do you know the ACIP-preferred influenza vaccine for adults aged ≥65 yrs? The cut-off age for HPV vaccination? The time between the 2-dose mpox series? More, here.
Pfizer/BioNTech Combination Flu/COVID-19 Shot Misses Key Primary Phase 3 Endpoint
The influenza/COVID-19 combination did not prove noninferior to the comparator flu vaccine against influenza B, the companies reported.
2024-25 Respiratory Virus Season: AAFP President on How to Get More Shots in Arms
Steven Furr, MD, discusses how communication between clinicians and patients is crucial to combatting vaccine hesitancy this upcoming respiratory virus season.
Routine Laboratory Study Results Not Clinically Useful for Diagnosing Long COVID: New Analysis
Of the 25 routine lab tests studied, none proved clinically useful for diagnosing COVID-19, even among participants with a high long COVID symptom burden.
Pfizer Reports Topline Data for Abrysvo Against RSV in Younger High-Risk Adults
RSVPreF induced strong neutralizing responses in immunocompromised adults aged 18 years and older in substudy B of the ongoing phase 3 MONET clinical trial.
10 States with the Lowest COVID-19 Vaccination Rates
Wyoming, Louisiana, and Oklahoma have the lowest percentage of population with shots in arms based on state population. Is your state among the other 7?
Long COVID Risk Declined Over the Pandemic: Daily Dose
ACIP Recommendations for RSV Vaccines in Older Adults: Update August 2024
The Advisory Committee on Immunization Practices' revisions prioritize vulnerable older adults and those at higher risk of severe infection.
Update: ACIP 2024 Adult Immunization Recommendations
This summary of updates to the ACIP 2024 Adult Vaccination recommendations includes 4 new vaccines and new formulations for COVID-19 and influenza shots.
Intranasal Flu Vaccine Coadministered with High-Dose Shot in Older Adults Superior Over Shot Alone: Daily Dose
Long COVID Risk Declined Over the Pandemic and Vaccination was Key, But Risk Remains
Ziyad Al-Aly, MD, and colleagues link 70% of the drop in cases to vaccine availability but caution the risk for long COVID remains significant.
Intranasal Flu Vaccine Coadministered with High-Dose Shot More Effective in Older Adults than Shot Alone
The investigational live intranasal vaccine was safe and well-tolerated when given concomitantly with Fluzone HD and the combination outperformed the latter given by itself.
7 Drugs Approved for Primary Care: Q2 2024
ICYMI: A quick look at 7 key drugs FDA-approved in the second quarter for conditions commonly seen in primary care.
Prenatal RSV Vaccine Not Associated with Preterm Birth, According to First Real-World Data
Data from a study performed during the first season the shot was available expand on clinical trial evidence and support the safety of RSVpreF, authors wrote.
UPDATE: ACIP Vote Unanimous to Recommend Merck 21-Valent Pneumococcal Shot for Older Adults
The novel vaccination is recommended as an option for adults aged 65 years and older who have not received a pneumococcal conjugate vaccine.
ACIP Revises Recommendation for Adult RSV Vaccination
The committee endorsed a universal recommendation for a single lifetime dose of RSV vaccine for adults aged ≥75 years and a risk-based recommendation for those aged 60 to 74 years.
FDA Gives Green Light to Ensifentrine for Maintenance Treatment of COPD in Adults
The dual PDE3/PDE4 inhibitor is the first inhaled product with a novel mechanism of action approved for COPD in 2 decades and is delivered via standard jet nebulizer.
Investigational Influenza-COVID-19 Combination Vaccine Elicits Immune Response in Older Adults: Daily Dose